AI Engines For more Details: Perplexity Kagi Labs You
Reduced Inflammation: Fluorometholone works by inhibiting the release of inflammatory mediators and suppressing the migration of inflammatory cells to the site of inflammation in the eye. This helps reduce swelling, redness, itching, and discomfort associated with inflammatory eye conditions.
Eye Conditions: Fluorometholone is commonly prescribed for the treatment of a wide range of eye conditions, including allergic conjunctivitis, non-infectious uveitis, keratitis, iritis, scleritis, episcleritis, and other inflammatory disorders of the eye.
Allergic Conjunctivitis: Allergic conjunctivitis is characterized by inflammation of the conjunctiva (the thin membrane covering the white part of the eye and the inner surface of the eyelids) due to exposure to allergens such as pollen, dust mites, pet dander, or certain medications. Fluorometholone eye drops can help alleviate symptoms such as itching, redness, tearing, and swelling associated with allergic conjunctivitis.
Non-Infectious Uveitis: Uveitis refers to inflammation of the uvea, the middle layer of the eye comprising the iris, ciliary body, and choroid. Non-infectious uveitis may be caused by autoimmune diseases, systemic infections, or other inflammatory conditions. Fluorometholone eye drops or ointment can help reduce intraocular inflammation and prevent complications associated with uveitis.
Keratitis and Iritis: Keratitis and iritis are inflammatory conditions affecting the cornea and iris, respectively. They may be caused by infections, trauma, autoimmune diseases, or other underlying conditions. Fluorometholone is often used in combination with antibiotics or other medications to reduce inflammation and promote healing in patients with keratitis or iritis.
Dosage and Administration: The dosage and frequency of fluorometholone eye drops or ointment depend on the specific eye condition being treated, the severity of symptoms, and the individual patient's response to treatment. It is typically administered as one or two drops into the affected eye(s) several times daily, as directed by a healthcare provider.
Side Effects: While fluorometholone is generally well-tolerated when used as directed, prolonged use or misuse may increase the risk of side effects, including increased intraocular pressure, cataract formation, delayed wound healing, glaucoma, and secondary eye infections. Patients should be monitored regularly for signs of adverse effects during treatment.
Contraindications: Fluorometholone eye drops or ointment should not be used in patients with certain eye infections (e.g., viral or fungal infections), tuberculosis of the eye, or hypersensitivity to corticosteroids or any other components of the medication. It should be used with caution in patients with a history of glaucoma or elevated intraocular pressure.
Drug Interactions: There are no known significant drug interactions with fluorometholone eye drops or ointment. However, patients should inform their healthcare provider about all medications, supplements, and eye drops they are using to avoid potential interactions or complications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 0.7 | 0.7 | |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0.4 | 0 |
| Allergic Rhinitis (Hay Fever) | 1.2 | 1.2 | |
| Allergies | 2.3 | 0 | 0 |
| Allergy to milk products | 1.2 | 0.9 | 0.33 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 2.2 | 1.3 | 0.69 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0.9 | 0.56 |
| Ankylosing spondylitis | 2.5 | 0.4 | 5.25 |
| Anorexia Nervosa | 0.4 | 0.3 | 0.33 |
| Antiphospholipid syndrome (APS) | 1.6 | 0.1 | 15 |
| Asthma | 0 | 0.3 | 0 |
| Atherosclerosis | 0 | 0.1 | 0 |
| Atrial fibrillation | 1 | 1.2 | -0.2 |
| Autism | 2.6 | 2.9 | -0.12 |
| Barrett esophagus cancer | 0 | 0.4 | 0 |
| benign prostatic hyperplasia | 0.5 | 0.5 | |
| Biofilm | 1.1 | 1.1 | |
| Bipolar Disorder | 1.1 | 0 | 0 |
| Brain Trauma | 0.3 | -0.3 | |
| Cancer (General) | 0.4 | -0.4 | |
| Carcinoma | 1.6 | 0.6 | 1.67 |
| Celiac Disease | 1.9 | 0.7 | 1.71 |
| Cerebral Palsy | 0.5 | 0.3 | 0.67 |
| Chronic Fatigue Syndrome | 2.2 | 2.6 | -0.18 |
| Chronic Kidney Disease | 1.2 | 0 | 0 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 0 | 0 |
| Chronic Urticaria (Hives) | 1.9 | 0.9 | 1.11 |
| Coagulation / Micro clot triggering bacteria | 2.2 | 0.5 | 3.4 |
| Colorectal Cancer | 4 | 4 | |
| Constipation | 1 | 0 | 0 |
| Coronary artery disease | 0.1 | 0.1 | |
| COVID-19 | 3.8 | 2.4 | 0.58 |
| Crohn's Disease | 3.5 | 1.6 | 1.19 |
| cystic fibrosis | 1.4 | 0.3 | 3.67 |
| deep vein thrombosis | 1.4 | 0.5 | 1.8 |
| Depression | 3.7 | 2.9 | 0.28 |
| Dermatomyositis | 0.4 | 0.4 | |
| Eczema | 0.6 | 2.2 | -2.67 |
| Endometriosis | 2.5 | 2.5 | |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 2.1 | 1.5 | 0.4 |
| Fibromyalgia | 1.4 | 0.5 | 1.8 |
| Functional constipation / chronic idiopathic constipation | 3.3 | 1.2 | 1.75 |
| gallstone disease (gsd) | 0.9 | 0.1 | 8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.4 | 2 |
| Generalized anxiety disorder | 1.6 | 0.2 | 7 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0.4 | -0.4 | |
| Graves' disease | 0.6 | 0 | 0 |
| Halitosis | 0.2 | 0.4 | -1 |
| Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 1 | 1 | |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.5 | 0.6 | -0.2 |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 1.5 | 1.8 | -0.2 |
| Hypoxia | 0.6 | 0.6 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 4 | 1.9 | 1.11 |
| Insomnia | 0.7 | 0.3 | 1.33 |
| Intelligence | 0.3 | 0 | 0 |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 1.8 | 1.2 | 0.5 |
| Liver Cirrhosis | 1.7 | 0.8 | 1.13 |
| Long COVID | 2.1 | 0.9 | 1.33 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.5 | 0.5 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | |
| ME/CFS with IBS | 0.5 | 0.2 | 1.5 |
| ME/CFS without IBS | 0.6 | 0.8 | -0.33 |
| Metabolic Syndrome | 3.6 | 2.7 | 0.33 |
| Mood Disorders | 3.8 | 2.9 | 0.31 |
| multiple chemical sensitivity [MCS] | 1.3 | 1.3 | |
| Multiple Sclerosis | 1.8 | 2.6 | -0.44 |
| neuropathic pain | 0.2 | -0.2 | |
| Neuropathy (all types) | 0.4 | 0.5 | -0.25 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 0.2 | 4 |
| NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
| Obesity | 1.7 | 1.9 | -0.12 |
| obsessive-compulsive disorder | 4.4 | 0.4 | 10 |
| Osteoarthritis | 1.2 | 1.2 | |
| Osteoporosis | 0.7 | 0.2 | 2.5 |
| pancreatic cancer | 0.4 | 0.4 | |
| Parkinson's Disease | 4.3 | 2 | 1.15 |
| Polycystic ovary syndrome | 1.4 | 0.1 | 13 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.2 | -0.2 | |
| Psoriasis | 2.3 | 1.3 | 0.77 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 1.2 | 0.5 |
| Rosacea | 0.1 | -0.1 | |
| Schizophrenia | 1 | 0.1 | 9 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 1.3 | 0.8 | 0.63 |
| Sleep Apnea | 0 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 1.2 | 1.2 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
| Stress / posttraumatic stress disorder | 1.6 | 0.3 | 4.33 |
| Systemic Lupus Erythematosus | 2.6 | 0 | 0 |
| Tic Disorder | 0.3 | 0 | 0 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 2 | 0.8 | 1.5 |
| Type 2 Diabetes | 3.9 | 3.6 | 0.08 |
| Ulcerative colitis | 2.3 | 1.3 | 0.77 |
| Unhealthy Ageing | 2.7 | 0 | 0 |
| Vitiligo | 1.3 | 0.4 | 2.25 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]
